Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop ADCs and SMDCs; and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory AML, higher-risk MDS, and B-ALL; VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies; VIP236, a small molecule-drug conjugate, which is in Phase 1 dose-escalation study in patients with advanced or metastatic solid tumors; and Enitociclib, a highly selective CDK9 inhibitor, which is in Phase 1 clinical trial. Vincerx Pharma, Inc. was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. The company was founded in 2019 and is based in San Mateo, California.